Last reviewed · How we verify

NCT05742399

Periocular Rejuvenation by Topical Hyaluronic Acid Nano Particles

Completed Phase 1, PHASE2 Last updated 31 January 2025
What this trial tests

Phase 1, PHASE2 trial testing Hyaluronic acid NanoGel in Tear Trough Eyelid Deformity in 30 participants. Completed in 15 January 2024.

Timeline
21 December 2022
Primary endpoint
15 September 2023
15 January 2024

Quick facts

Lead sponsorAlexandria University
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment30
Start date21 December 2022
Primary completion15 September 2023
Estimated completion15 January 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 21 to 65, any sex, with Tear Trough Eyelid Deformity or Dark Eyelids. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, The investigators aims to evaluate the efficacy and safety of topical hyaluronic acid nanoparticles as a novel nanodermatological tool in periocular rejuvenation as a replacement approach of invasive dermal filler injections.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Progress in Topical and Transdermal Drug Delivery Research-Focus on Nanoformulations.
    Lunter D, Klang V, Eichner A, Savic SM, et al · · 2024 · cited 22× · PMID 38931938 · DOI 10.3390/pharmaceutics16060817
  2. Inflammation-modulating polymeric nanoparticles: design strategies, mechanisms, and therapeutic applications.
    Zhang H, Chen H, Hu X, Muhammad W, et al · · 2025 · cited 8× · PMID 40614330 · DOI 10.1016/j.ebiom.2025.105837
  3. Bioresponsive engineered nanoparticles for immunomodulation.
    Hegde M, Mishra A, Banerjee R, Bintee B, et al · · 2025 · cited 4× · PMID 41162977 · DOI 10.1186/s12916-025-04305-6

Verify or expand the search:

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05742399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing